Illumina, Inc.
ILMNNasdaqLaboratory Analytical InstrumentsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 30, 2026Score 14/308% above fair value
$192.82−7.84 (-3.90%)
Close on Nov 20, 2026Market cap $29.15BP/E 33.1Yield –
Illumina Sequencing Product Revenue: $866M in Q3 2026, up 1.4% from a year earlier.
Latest, Q3 2026
866
Period ended Sep 30, 2026
Change on a year earlier
+1.4%
854 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
34
Documents cited below
Where the Q3 2026 figure comes from
Source: Illumina Form 10-Q for Q3 2026 (filed 2026-10-30) ↗
Reported in SEC Form 10-K / Form 10-Q (Note 2 — Revenue by Source).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up sequencing Product Revenue
Cite this data
StockData. (2026). Illumina Sequencing Product Revenue ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Illumina SEC filings and investor materials. https://stockdatahq.com/stocks/ilmn/kpis/seq-product-rev
See every metric in the Illumina KPI table. Data updated Nov 9, 2026.
See a number that looks wrong?